About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 51 results
Filters: Author is Horowitz, Mary M  [Clear All Filters]
2022
A. E. DeZern, Eapen, M., Wu, J., Talano, J. - A., Solh, M., Saldaña, B. J. Dávila, Karanes, C., Horwitz, M. E., Mallhi, K., Arai, S., Farhadfar, N., Hexner, E., Westervelt, P., Antin, J. H., H Deeg, J., Leifer, E., Brodsky, R. A., Logan, B. R., Horowitz, M. M., Jones, R. J., and Pulsipher, M. A., Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial., Lancet Haematol, 2022.
C. G. Brunstein, O'Donnell, P. V., Logan, B., Dawson, P., Costa, L., Cutler, C., Craig, M., Hogan, W., Horowitz, M. M., Horwitz, M. E., Karanes, C., Magenau, J. M., Malone, A., McCarty, J., McGuirk, J. P., Morris, L. E., Rezvani, A. R., Salit, R., Vasu, S., Eapen, M., and Fuchs, E. J., Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012., Transplant Cell Ther, vol. 28, no. 7, pp. 406.e1-406.e6, 2022.
L. Luznik, Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, A., Muffly, L., Nemecek, E. R., O'Donnell, L., O'Reilly, R. J., Palencia, R., Schetelig, J., Shune, L., Solomon, S. R., Vasu, S., Ho, V. T., and Perales, M. - A., Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies., J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
A. D'Souza, Brazauskas, R., Stadtmauer, E. A., Pasquini, M. C., Hari, P., Bashey, A., Callander, N., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Landau, H., Brunstein, C., McCarthy, P., Qazilbash, M. H., Giralt, S., Krishnan, A., and Flynn, K. E., Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma., Am J Hematol, 2022.
P. V. O'Donnell, Brunstein, C. G., Fuchs, E. J., Zhang, M. - J., Allbee-Johnson, M., Antin, J. H., Leifer, E. S., Elmariah, H., Grunwald, M. R., Hashmi, H., Horowitz, M. M., Magenau, J. M., Majhail, N., Milano, F., Morris, L. E., Rezvani, A. R., McGuirk, J. P., Jones, R. J., and Eapen, M., Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes., Transplant Cell Ther, vol. 28, no. 2, pp. 109.e1-109.e8, 2022.
2021
H. E. Heslop, Stadtmauer, E. A., Levine, J. E., Ballen, K. K., Bin Chen, Y. -, DeZern, A. E., Eapen, M., Hamadani, M., Hamilton, B. K., Hari, P., Jones, R. J., Logan, B. R., Kean, L. S., Leifer, E. S., Locke, F. L., Maziarz, R. T., Nemecek, E. R., Pasquini, M., Phelan, R., Riches, M. L., Shaw, B. E., Walters, M. C., Foley, A., Devine, S. M., and Horowitz, M. M., Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year., Transplant Cell Ther, vol. 27, no. 11, pp. 885-907, 2021.
E. D. Warlick, Ustun, C., Andreescu, A., Bonagura, A. F., Brunner, A., Chandra, A. B., Foran, J. M., Juckett, M. B., Kindwall-Keller, T. L., Klimek, V. M., Pease, D. F., Steensma, D. P., Waldman, B. M., Horowitz, M. M., Burns, L. J., and Khera, N., Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation., Cancer, vol. 127, no. 23, pp. 4339-4347, 2021.
S. M. Devine and Horowitz, M. M., Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies., J Clin Oncol, vol. 39, no. 5, pp. 534-544, 2021.
E. J. Fuchs, O'Donnell, P. V., Eapen, M., Logan, B., Antin, J. H., Dawson, P., Devine, S., Horowitz, M. M., Horwitz, M. E., Karanes, C., Leifer, E., Magenau, J. M., McGuirk, J. P., Morris, L. E., Rezvani, A. R., Jones, R. J., and Brunstein, C. G., Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial., Blood, vol. 137, no. 3, pp. 420-428, 2021.
N. Farhadfar, Burns, L. J., Mupfudze, T., Shaw, B. E., Bollard, C. M., Devine, S. M., Horowitz, M. M., Jones, R. J., Murthy, H. S., Wingard, J. R., and Lee, S. J., Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023., Transplant Cell Ther, vol. 27, no. 2, pp. 183.e1-183.e7, 2021.
J. R. Wingard, Alexander, B. D., Baden, L. R., Chen, M., Sugrue, M. W., Leather, H. L., Caliendo, A. M., Clancy, C. J., Denning, D. W., Marty, F. M., M Nguyen, H., L Wheat, J., Logan, B. R., Horowitz, M. M., and Marr, K. A., Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?, Open Forum Infect Dis, vol. 8, no. 10, p. ofab441, 2021.
B. L. Scott, Pasquini, M. C., Fei, M., Fraser, R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E., Fernandez, H. F., Soiffer, R. J., Alyea, E., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Hourigan, C. S., Gui, G., Mendizabal, A., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial., Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
2019
R. F. Ambinder, Wu, J., Logan, B., Durand, C. M., Shields, R., Popat, U. R., Little, R. F., McMahon, D. K., Cyktor, J., Mellors, J. W., Ayala, E., Kaplan, L. D., Noy, A., Jones, R. J., Howard, A., Forman, S. J., Porter, D., Arce-Lara, C., Shaughnessy, P., Sproat, L., Hashmi, S. K., Mendizabal, A. M., Horowitz, M. M., Navarro, W. H., and Alvarnas, J. C., Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial., Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
E. A. Stadtmauer, Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Knust, K., Landau, H., Brunstein, C., McCarthy, P., Nelson, C., Qazilbash, M. H., Shah, N., Vesole, D. H., Vij, R., Vogl, D. T., Giralt, S., Somlo, G., and Krishnan, A., Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial., J Clin Oncol, vol. 37, no. 7, pp. 589-597, 2019.
M. J. Levis, Bin Chen, Y. -, Hamadani, M., Horowitz, M. M., and Jones, R. J., FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?, J Clin Oncol, vol. 37, no. 19, pp. 1604-1607, 2019.
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with , Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.
2018
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials., Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
R. Spellecy, Tarima, S., Denzen, E., Moore, H., Abhyankar, S., Dawson, P., Foley, A., Gersten, I., Horwitz, M., Idossa, L., Joffe, S., Kamani, N., King, R., Lazaryan, A., Morris, L., Horowitz, M. M., and Majhail, N. S., Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study., Biol Blood Marrow Transplant, vol. 24, no. 10, pp. 2145-2151, 2018.
P. A. Carpenter, Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., Kitko, C. L., Bolaños-Meade, J., Sarantopoulos, S., Alousi, A. M., Abhyankar, S., Waller, E. K., Mendizabal, A., Zhu, J., O'Brien, K. A., Lazaryan, A., Wu, J., Nemecek, E. R., Pavletic, S. Z., Cutler, C. S., Horowitz, M. M., and Arora, M., A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801., Haematologica, vol. 103, no. 11, pp. 1915-1924, 2018.
N. Khera, Mau, L. - W., Denzen, E. M., Meyer, C., Houg, K., Lee, S. J., Horowitz, M. M., and Burns, L. J., Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization., Biol Blood Marrow Transplant, vol. 24, no. 11, pp. 2204-2210, 2018.
2017
B. L. Scott, Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Le-Rademacher, J., Mendizabal, A. M., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes., J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
M. Eapen, Kurtzberg, J., Zhang, M. - J., Hattersely, G., Fei, M., Mendizabal, A., Chan, K. Wah, De Oliveira, S., Schultz, K. R., Wall, D., Horowitz, M. M., and Wagner, J. E., Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes., Biol Blood Marrow Transplant, vol. 23, no. 10, pp. 1714-1721, 2017.
S. A. Holstein, Jung, S. - H., Richardson, P. G., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., van Besien, K., Gentile, T. G., Isola, L., Maziarz, R. T., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Rodriguez, C., McClune, B., Schlossman, R. L., Smith, S. E., Hars, V., Owzar, K., Jiang, C., Boyd, M., Schultz, C., Wilson, M., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Linker, C., Anderson, K. C., and McCarthy, P. L., Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial., Lancet Haematol, vol. 4, no. 9, pp. e431-e442, 2017.